Other
Radioconjugate
Radioconjugate is an intervention with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting1
Not yet recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
recruiting133%
not_yet_recruiting133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT06039371
not_yet_recruitingphase_1
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
NCT07608627
withdrawnphase_1
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
NCT06427369
Clinical Trials (3)
Showing 3 of 3 trials
NCT06039371Phase 2
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT07608627Phase 1
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
NCT06427369Phase 1
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3